Simsen Diagnostics Selected for Business Sweden’s Catalyst Program 

Gothenburg 27th of March – Simsen Diagnostics is excited to announce their selection for Business Sweden’s prestigious Catalyst program, which is a significant step in the company’s journey towards international expansion. 

The Catalyst program, designed for the most innovative and promising startups in Sweden, aims to provide tailored support to accelerate international growth in chosen markets. Simsen Diagnostics has identified the UK as its target market due to its status as the world’s leading biotech cluster and the presence of a substantial customer base. 

Simsen Diagnostics is revolutionizing cancer care through its advanced technology for monitoring ctDNA, a biomarker directly correlated with tumor burden. With the help of Simsen Diagnostics’ ultrasensitive tools cancer can be monitored and relapse detected years before standard-of-care tools. The technology can aid in evaluating treatment responses, detecting relapses, and identifying remaining disease. 

“We’re beyond excited to have been selected for the Catalyst program,” said Camilla Hietanen, Sales Manager, at Simsen Diagnostics. “Expanding into the UK market is a strategic move for us, given its prominence in the biotech sector. We’re excited about the opportunity to introduce our ctDNA assessment technology to this market.” 

Participation in the Catalyst program and the subsequent launch of Simsen Diagnostics’ technology in the UK market are important steps towards establishing the company as a leader in ctDNA assessment across Europe. The company looks forward to collaborating with the talented team in the UK and working towards its goal of transforming cancer care. 

About Simsen Diagnostics 

Simsen Diagnostics is a biotech startup focusing on transforming cancer monitoring. Specializing in designing patient-specific tests, Simsen Personal, the flagship solution, is based on ultrasensitive technology capable of detecting cancer years before standard-of-care tools. Founded in 2020 as a research spin-out from Sahlgrenska Academy, Simsen Diagnostics has experienced steady growth, gaining recognition from the pharmaceutical industry. Situated in BioventureHub at AstraZeneca Gothenburg, the company is at the forefront of providing innovative solutions in cancer monitoring. 

Pontus Rehn

Chief Executive Officer (CEO)

Pontus Rehn has over 20 years of experience in commercial leadership roles in the medical device and IVD industries, including global and regional positions like VP Market Development, Chief Commercial Officer, and Director of Commercial Strategy. 

Lina Said

Laboratory and Quality Manager

Lina Said, a licensed Biomedical Scientist, brings 18 years of experience from Sahlgrenska University Hospital to her role as the Lab and Quality Manager at Simsen Diagnostics. Her primary focus is ensuring quality assurance and fostering an optimal work environment for the lab. 

My Vu

Lead Laboratory Technician

My Vu is currently doing a master’s degree in biotechnology and demonstrates expertise in laboratory procedures. Her previous experience includes analyzing COVID samples and conducting her bachelor’s thesis at Fraunhofer. My is analyzing all the samples that comes to the lab.  

Stefan Filges

Chief Technology Officer (CTO)

Stefan Filges, an accomplished bioinformatician with a Ph.D. in ultrasensitive sequencing, became part of Simsen Diagnostics in 2022. He played a crucial role as a co-author in the original publication of SiMSen-Seq, which was published in Nature Protocols. 

Camilla Hietanen

Head of Sales and Marketing

Camilla Hietanen holds an M.Sc. in Business Development from the Chalmers School of Entrepreneurship. Her academic background encompasses studies in Sports & Nutrition, and she brings prior experience from various Start-ups. Within Simsen Diagnostics, her primary focus lies in Sales and Marketing. 

Almost there

Sign up on our maillist to gain access to your article. You can at any time unsubscribe from the list.